Amgen (4332) Stock Forecast & Price Target

Compare

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

4332 Analyst Ratings

Moderate Buy

8 Buy

11 Hold

1 Sell

Based on 20 analysts giving stock ratings to

Amgen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

4332 Stock 12 Month Forecast

Average Price Target

HK$2,518.46

―

Based on 20 Wall Street analysts offering 12 month price targets for Amgen in the last 3 months. The average price target is HK$2,518.46 with a high forecast of HK$3,150.40 and a low forecast of HK$2,115.83. The average price target represents a 1399041.74% change from the last price of HK$0.18.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1687":"HK$1,687","2053":"HK$2,053","2419":"HK$2,419","2785":"HK$2,785","3151":"HK$3,151"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3150.40255065,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$3.15K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2518.4551353048,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$2.52K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2115.82591056,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$2.12K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1687,2053,2419,2785,3151],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1761,1867.8771192807692,1974.7542385615384,2081.631357842308,2188.508477123077,2295.385596403846,2402.2627156846156,2509.1398349653846,2616.016954246154,2722.8940735269234,2829.7711928076924,2936.648312088462,3043.5254313692312,{"y":3150.40255065,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1761,1819.2657796388307,1877.5315592776615,1935.7973389164922,1994.0631185553232,2052.3288981941537,2110.5946778329844,2168.8604574718156,2227.1262371106463,2285.392016749477,2343.657796388308,2401.9235760271386,2460.1893556659693,{"y":2518.4551353048,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1761,1788.2943008123077,1815.5886016246154,1842.8829024369231,1870.1772032492308,1897.4715040615386,1924.7658048738463,1952.0601056861537,1979.3544064984615,2006.6487073107692,2033.9430081230769,2061.2373089353846,2088.5316097476925,{"y":2115.82591056,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1688.903,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1688.903,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1688.903,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1705.868,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1705.868,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1705.868,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1724.001,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1724.001,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1724.001,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1742.403,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1742.403,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1742.403,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1761,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetHK$3,150

Average Price TargetHK$2,518

Lowest Price TargetHK$2,116

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Veda Pharmyne

TR | OpenAI - 4o

HK$2,463.02→HK$2,447.48

Buy

1359609.10%

Upside

Upgraded

09/23/25

AI Generated ArticleAI Generated Article

David Amsellem

Piper Sandler

HK$2,657.26

Buy

1476155.60%

Upside

Reiterated

09/18/25

Piper Sandler Reaffirms Their Buy Rating on Amgen (AMGN)

Chris Schott

J.P. Morgan

HK$2,330.93

Hold

1294861.05%

Upside

Reiterated

09/16/25

J.P. Morgan Reaffirms Their Hold Rating on Amgen (AMGN)

Vamil Divan

Guggenheim

HK$2,237.69

Hold

1243062.61%

Upside

Reiterated

09/05/25

Amgen (AMGN) Gets a Hold from Guggenheim

Christopher Raymond

Raymond James

―

Hold

―

Reiterated

09/04/25

Amgen assumed with a Market Perform at Raymond JamesAmgen assumed with a Market Perform at Raymond James

Matt Phipps

William Blair

―

Buy

―

Reiterated

09/03/25

Amgen's Strategic Focus and Portfolio Strength Justify Buy Rating Despite Bemarituzumab Challenges

David Risinger

Leerink Partners

―

Hold

―

Reiterated

08/25/25

Amgen's Repatha: Balancing Growth Potential with Long-Term Risks

Salim Syed

Mizuho Securities

HK$2,175.53

Hold

1208530.31%

Upside

Reiterated

08/18/25

Mizuho Securities Keeps Their Hold Rating on Amgen (AMGN)

Courtney Breen

Bernstein

HK$2,602.87

Buy

1445939.84%

Upside

Reiterated

08/17/25

We rate LLY, GILD, AMGN Outperform.

Carter Gould

Cantor Fitzgerald

HK$2,369.78

Hold

1316443.73%

Upside

Reiterated

08/13/25

Cantor Fitzgerald Reaffirms Their Hold Rating on Amgen (AMGN)

Yaron Werber

TD Cowen

HK$3,022.44

Buy

1679032.83%

Upside

Reiterated

08/06/25

Amgen: Strong Financial Performance and Promising Growth Prospects Drive Buy Rating

Trung Huynh

UBS

HK$2,532.94→HK$2,463.02

Hold

1368242.17%

Upside

Reiterated

08/06/25

Amgen price target lowered to $317 from $326 at UBSAmgen price target lowered to $317 from $326 at UBS

Tim Anderson

Bank of America Securities

HK$2,027.91→HK$2,113.38

Sell

1173998.02%

Upside

Reiterated

08/06/25

Amgen's Underperform Rating: Concerns Over R&D Expenses and Trial Strategy Impacting Future Growth

Mohit Bansal

Wells Fargo

HK$2,602.87→HK$2,175.53

Hold

1208530.31%

Upside

Reiterated

08/06/25

Amgen (AMGN) Receives a Hold from Wells Fargo

Salveen Richter

Goldman Sachs

HK$3,107.91→HK$3,146.76

Buy

1748097.42%

Upside

Reiterated

08/06/25

Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (NASDAQ: PRCT), Amgen (NASDAQ: AMGN) and Qiagen (NYSE: QGEN)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Veda Pharmyne

TR | OpenAI - 4o

HK$2,463.02→HK$2,447.48

Buy

1359609.10%

Upside

Upgraded

09/23/25

AI Generated ArticleAI Generated Article

David Amsellem

Piper Sandler

HK$2,657.26

Buy

1476155.60%

Upside

Reiterated

09/18/25

Piper Sandler Reaffirms Their Buy Rating on Amgen (AMGN)

Chris Schott

J.P. Morgan

HK$2,330.93

Hold

1294861.05%

Upside

Reiterated

09/16/25

J.P. Morgan Reaffirms Their Hold Rating on Amgen (AMGN)

Vamil Divan

Guggenheim

HK$2,237.69

Hold

1243062.61%

Upside

Reiterated

09/05/25

Amgen (AMGN) Gets a Hold from Guggenheim

Christopher Raymond

Raymond James

―

Hold

―

Reiterated

09/04/25

Amgen assumed with a Market Perform at Raymond JamesAmgen assumed with a Market Perform at Raymond James

Matt Phipps

William Blair

―

Buy

―

Reiterated

09/03/25

Amgen's Strategic Focus and Portfolio Strength Justify Buy Rating Despite Bemarituzumab Challenges

David Risinger

Leerink Partners

―

Hold

―

Reiterated

08/25/25

Amgen's Repatha: Balancing Growth Potential with Long-Term Risks

Salim Syed

Mizuho Securities

HK$2,175.53

Hold

1208530.31%

Upside

Reiterated

08/18/25

Mizuho Securities Keeps Their Hold Rating on Amgen (AMGN)

Courtney Breen

Bernstein

HK$2,602.87

Buy

1445939.84%

Upside

Reiterated

08/17/25

We rate LLY, GILD, AMGN Outperform.

Carter Gould

Cantor Fitzgerald

HK$2,369.78

Hold

1316443.73%

Upside

Reiterated

08/13/25

Cantor Fitzgerald Reaffirms Their Hold Rating on Amgen (AMGN)

Yaron Werber

TD Cowen

HK$3,022.44

Buy

1679032.83%

Upside

Reiterated

08/06/25

Amgen: Strong Financial Performance and Promising Growth Prospects Drive Buy Rating

Trung Huynh

UBS

HK$2,532.94→HK$2,463.02

Hold

1368242.17%

Upside

Reiterated

08/06/25

Amgen price target lowered to $317 from $326 at UBSAmgen price target lowered to $317 from $326 at UBS

Tim Anderson

Bank of America Securities

HK$2,027.91→HK$2,113.38

Sell

1173998.02%

Upside

Reiterated

08/06/25

Amgen's Underperform Rating: Concerns Over R&D Expenses and Trial Strategy Impacting Future Growth

Mohit Bansal

Wells Fargo

HK$2,602.87→HK$2,175.53

Hold

1208530.31%

Upside

Reiterated

08/06/25

Amgen (AMGN) Receives a Hold from Wells Fargo

Salveen Richter

Goldman Sachs

HK$3,107.91→HK$3,146.76

Buy

1748097.42%

Upside

Reiterated

08/06/25

Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (NASDAQ: PRCT), Amgen (NASDAQ: AMGN) and Qiagen (NYSE: QGEN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Amgen

1 Month

xxx

Success Rate

21/40 ratings generated profit

Average Return

+0.74%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 52.50% of your transactions generating a profit, with an average return of +0.74% per trade.

3 Months

xxx

Success Rate

24/40 ratings generated profit

Average Return

+4.28%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +4.28% per trade.

1 Year

Yaron WerberTD Cowen

Success Rate

28/40 ratings generated profit

Average Return

+10.89%

reiterated a buy rating 2 months ago

Copying Yaron Werber's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +10.89% per trade.

2 Years

xxx

Success Rate

40/54 ratings generated profit

Average Return

+16.03%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 74.07% of your transactions generating a profit, with an average return of +16.03% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4332 Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 4332 has received 24 Buy Ratings, 22 Hold Ratings, and 2 Sell Ratings. 4332 average Analyst price target in the past 3 months is 2,518.46.

Each month's total comprises the sum of three months' worth of ratings.

4332 Financial Forecast

4332 Earnings Forecast

Next quarter’s earnings estimate for 4332 is HK$39.19 with a range of HK$32.65 to HK$42.44. The previous quarter’s EPS was HK$46.79. 4332 beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.11% of the time in the same period. In the last calendar year 4332 has Outperformed its overall industry.

4332 Sales Forecast

Next quarter’s sales forecast for 4332 is HK$69.82B with a range of HK$68.24B to HK$71.50B. The previous quarter’s sales results were HK$71.25B. 4332 beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year 4332 has Outperformed its overall industry.

4332 Stock Forecast FAQ

What is HK:4332’s average 12-month price target, according to analysts?

Based on analyst ratings, Amgen Inc’s 12-month average price target is 2,518.46.

What is HK:4332’s upside potential, based on the analysts’ average price target?

Amgen Inc has 1399041.74% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Amgen Inc a Buy, Sell or Hold?

Amgen Inc has a consensus rating of Moderate Buy, which is based on 8 buy ratings, 11 hold ratings and 1 sell ratings.

What is Amgen Inc’s share price target?

The average share price target for Amgen Inc is 2,518.46. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is HK$3,150.40 ,and the lowest forecast is HK$2,115.83. The average share price target represents 1399041.74% Increase from the current price of HK$0.18.

What do analysts say about Amgen Inc?

Amgen Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of Amgen Inc?

To buy shares of HK:4332, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Amgen (4332) Stock Forecast & Price Target

4332 Analyst Ratings

4332 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Amgen

4332 Analyst Recommendation Trends

4332 Financial Forecast

4332 Earnings Forecast

4332 Sales Forecast

4332 Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts